Brustkrebs | ICD10: C50

88 KB  

Multicenter, interventional, prospective, two-arm, randomized, open-label, controlled (neo)adjuvant, phase-III trial evaluating the efficacy and safety of ribociclib combined with endocrine therapy (ET) versus standard-of-care chemotherapy in early breast cancer (EBC) patients with molecular HR+/HER2- subtype.

48 KB  

A Prospective Multicenter Cohort Study to Evaluate Different Surgical Methods of Axillary Staging (Sentinel Lymph Node Biopsy, Targeted Axillary Dissection, Axillary Dissection) in Clinically Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

107 KB  

Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

60 KB  

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy

55 KB  

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting

54 KB  

Eine multizentrische, zweiteilige, offene Studie der Phase Ib zu DS-8201a, einem antihumanen epidermalen Wachstumsfaktor-Rezeptor-2(HER2)-Antikörper-Wirkstoff-Konjugat (ADC) in Kombination mit Nivolumab, einem Anti-PD1-Antikörper für Patienten mit HER2-exprimierendem fortgeschrittenem Mamma- und Urothelkarzinom

57 KB  

A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor

57 KB  

Umfrage bei Patientinnen mt Eierstock. Eileiter-. Bauchfell-. oder Brustkrebs mit einer Krankheitszeit von mindestens 8 Jahren (gerechnet von dem Zeitpunkt der Erstdiagnose)

27 KB  

ILC-Register-Studie

19,42 KB  

Dynamics of therapy response and resistance in triple negative breast cancer – Integration of clinical trials and tumor organoid cellular models

46 KB  

Prevention of paclitaxel-related neurological side effects with lithium carbonate – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity (PREPARE trial)

26 KB  

Patient-Reported Outcomes bei Brusterkrankungen - Neue Wege in der Versorgung bei metastasiertem Brustkrebs

194 KB  

Phase-III-Studie zur postneoadjuvanten Behandlung von Sacituzumab Govitecan, einem Antikörper-Medikamenten-Konjugat bei primärem HER2-negativem Brustkrebspatienten mit hohem Rückfallrisiko nach einer Standard Neoadjuvante Chemotherapie (SASCIA)

32 KB  

A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases